MedTrace Logo

Mucosal Gene Expression Defects in IBD

NCT00639821 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2012-10-22

No results posted yet for this study

Summary

This study investigated the mucosal gene expression defects associated with active Crohn's disease (CD)and ulcerative colitis (UC), and studied the effect of infliximab induced downregulation of inflammation and mucosal healing on these abnormalities, using whole genome gene expression microarrays.

Conditions

  • Inflammatory Bowel Diseases

Sponsors & Collaborators

  • Fund for Scientific Research, Flanders, Belgium

    collaborator OTHER

  • KU Leuven

    lead OTHER

Principal Investigators

  • Paul Rutgeerts, MD, PhD · University of Leuven

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00639821 on ClinicalTrials.gov